News
29 Sep 2023
Q1 - FY24 - Highlights
Syngene revenue up 26% to Rs. 832 crores, PAT up 26% to Rs.93
crores in the first quarter (1) Acquisition of biologics manufacturing facility in Bangalore to complete by the end
of the third quarter in FY 24
(2) US FDA approval for API manufacturing plant in Mangalore received
(3) Acquisition of land in Hyderabad to support long term growth in research services
Q1 - FY24 - Highlights
Mentioned Companies
Syngene International Ltd.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance